Press Releases

Date Title  
Toggle Summary Audentes Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results and Provide Corporate Update on Thursday, March 8, 2018
-- Conference Call and Webcast to Follow -- SAN FRANCISCO , March 1, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare
Toggle Summary Audentes Therapeutics Joins Global Organizations In Recognizing Rare Disease Day® 2018
SAN FRANCISCO , Feb. 28, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced its support for Rare
Toggle Summary Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
- Preliminary data from VALENS expected to be available in the second quarter of 2018 - Rare Pediatric Disease and Fast Track designations for AT342 granted by FDA SAN FRANCISCO , Feb. 12, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on
Toggle Summary Audentes Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
SAN FRANCISCO , Feb. 8, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R.
Toggle Summary Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
- AAV8 vector containing a novel hybrid promoter selected based on findings of robust, comparative study in mouse model of Pompe disease - Results presented today at 14th Annual WORLDSymposium 2018 - Plan to file AT982 IND in the second quarter of 2018 - Plan to initiate a Phase 1 / 2 clinical
Toggle Summary Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
- AAV8 vector containing a novel hybrid promoter selected based on findings of robust, comparative study in mouse model of Pompe disease - Results presented today at 14th Annual WORLDSymposium 2018 - Plan to file AT982 IND in the second quarter of 2018 - Plan to initiate a Phase 1 / 2 clinical
Toggle Summary Audentes Therapeutics Announces Selection of Optimized Clinical Development Candidate for Pompe Disease Program
- AAV8 vector containing a novel hybrid promoter selected based on findings of robust, comparative study in mouse model of Pompe disease - Results presented today at 14th Annual WORLDSymposium 2018 - Plan to file AT982 IND in the second quarter of 2018 - Plan to initiate a Phase 1 / 2 clinical
Toggle Summary Audentes Therapeutics Announces the Closing of its Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO , Jan. 29, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the closing of its
Toggle Summary Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO , Jan. 24, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its
Toggle Summary Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO , Jan. 23, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends to offer